{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:59:00Z","timestamp":1788872340330,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["FPR08A2-130"],"award-info":[{"award-number":["FPR08A2-130"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["A070001"],"award-info":[{"award-number":["A070001"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.cca.2011.06.040","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T16:49:54Z","timestamp":1311439794000},"page":"2343-2345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low dose requirement for warfarin treatment in a patient with CYP2C9*3\/*13 genotype"],"prefix":"10.1016","volume":"412","author":[{"given":"Min-Jung","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Keun","family":"On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseong","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Wook","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2011.06.040_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01061991","article-title":"Bleeding complications to long-term oral anticoagulant therapy","volume":"1","author":"Gullov","year":"1994","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cca.2011.06.040_bb0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe0800801","article-title":"Pharmacogenomics\u2013ready for prime time?","volume":"358","author":"Shurin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2011.06.040_bb0015","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2011.06.040_bb0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003088-200140080-00003","article-title":"Pharmacogenetics of warfarin elimination and its clinical implications","volume":"40","author":"Takahashi","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2011.06.040_bb0030","first-page":"515","article-title":"Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application","volume":"29","author":"Kwon","year":"2009","journal-title":"Korean J Lab Med"},{"key":"10.1016\/j.cca.2011.06.040_bb0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cca.2011.06.040_bb0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/ajhp\/60.13.1319","article-title":"Interaction of rofecoxib and celecoxib with warfarin","volume":"60","author":"Schaefer","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cca.2011.06.040_bb0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1592\/phco.27.5.675","article-title":"The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy","volume":"27","author":"Parra","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cca.2011.06.040_bb0050","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1592\/phco.21.9.886.34556","article-title":"Fenofibrate and warfarin interaction","volume":"21","author":"Aldridge","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cca.2011.06.040_bb0055","first-page":"243","article-title":"Warfarin pharmacogenomics","volume":"11","author":"Cavallari","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.cca.2011.06.040_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.fpc.0000114749.08559.e4","article-title":"Identification of a novel variant CYP2C9 allele in Chinese","volume":"14","author":"Si","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cca.2011.06.040_bb0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/00498250903134435","article-title":"Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects","volume":"39","author":"Li","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cca.2011.06.040_bb0070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1124\/dmd.105.003616","article-title":"Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans","volume":"33","author":"Guo","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cca.2011.06.040_bb0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.fpc.0000184955.08453.a8","article-title":"Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans","volume":"16","author":"Takahashi","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cca.2011.06.040_bb0080","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","article-title":"Allele and genotype frequencies of CYP2C9 in a Korean population","volume":"60","author":"Bae","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2011.06.040_bb0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3346\/jkms.2007.22.3.557","article-title":"A case report of a patient carrying CYP2C9*3\/*4 genotype with extremely low warfarin dose requirement","volume":"22","author":"Lee","year":"2007","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.cca.2011.06.040_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FPC.0b013e32831a9ae3","article-title":"Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement","volume":"19","author":"Kim","year":"2009","journal-title":"Pharmacogenet Genomics"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898111003743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898111003743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:01:01Z","timestamp":1762113661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898111003743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":17,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0009898111003743"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2011.06.040","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose requirement for warfarin treatment in a patient with CYP2C9*3\/*13 genotype","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2011.06.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}